Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Peru to punish bending of clinical-trial rules

Peru’s National Institute of Health (INS) is urgently reviewing its procedures for authorization and supervision of clinical trials for COVID-19 treatments and vaccines, after protocol deviations in one such trial (see Nature 592, 174–175 (2021) and C. F. Cáceres et al. Nature 592, 685; 2021). Now under investigation by a regulatory body, the incident dented public confidence in the integrity of our scientific community.

The INS aims to ensure that such irregularities can never happen again. It plans to create a National Bioethics Commission, to establish a sanctions procedure and to upgrade training in ethics and scientific integrity for researchers.

There are currently 28 other clinical trials related to COVID-19 (4 vaccines and 24 treatments) in progress in Peru. All conform to international ethical and scientific standards.

Nature 595, 650 (2021)


Competing Interests

The authors declare no competing interests.


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links